INT45503

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1984
Last Reported 2010
Negated 2
Speculated 0
Reported most in Body
Documents 42
Total Number 42
Disease Relevance 24.85
Pain Relevance 2.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (EPO) extracellular space (EPO) aging (EPO)
extracellular region (EPO)
Anatomy Link Frequency
red blood cell 3
blood 3
neurons 2
skeletal muscle myoblasts 1
brain 1
EPO (Homo sapiens)
Pain Link Frequency Relevance Heat
Enkephalin 1 100.00 Very High Very High Very High
headache 25 99.30 Very High Very High Very High
Pain 11 98.84 Very High Very High Very High
cytokine 26 97.32 Very High Very High Very High
cva 61 96.40 Very High Very High Very High
anticonvulsant 1 96.04 Very High Very High Very High
Versed 2 91.44 High High
palliative 10 86.76 High High
ischemia 19 85.04 High High
Clonidine 7 84.48 Quite High
Disease Link Frequency Relevance Heat
Anaemia 608 100.00 Very High Very High Very High
Cancer 340 100.00 Very High Very High Very High
Renal Disease 10 100.00 Very High Very High Very High
Leukoencephalopathies 2 99.92 Very High Very High Very High
Chronic Renal Failure 40 99.78 Very High Very High Very High
Apoptosis 50 99.52 Very High Very High Very High
Hypertension 24 99.32 Very High Very High Very High
Injury 66 99.30 Very High Very High Very High
Disease 114 99.06 Very High Very High Very High
Thrombosis 14 98.88 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Alopecia in three women of Southeast Asian descent with chronic renal failure: possible association with erythropoietin use.
erythropoietin Binding (association) of associated with chronic renal failure and alopecia
1) Confidence 0.48 Published 2001 Journal Am. J. Kidney Dis. Section Title Doc Link 11136198 Disease Relevance 1.23 Pain Relevance 0.13
We report a potentially new side effect associated with Epo of a cosmetic nature.
Epo Binding (associated) of
2) Confidence 0.48 Published 2001 Journal Am. J. Kidney Dis. Section Abstract Doc Link 11136198 Disease Relevance 1.25 Pain Relevance 0.14
Two cases were strongly associated with Epo use, and a third had other intercurrent illnesses as well.
Epo Binding (associated) of
3) Confidence 0.48 Published 2001 Journal Am. J. Kidney Dis. Section Abstract Doc Link 11136198 Disease Relevance 1.18 Pain Relevance 0.13
Hypertensive posterior leukoencephalopathy is associated with erythropoietin use.
erythropoietin Binding (associated) of in posterior associated with hypertension and leukoencephalopathies
4) Confidence 0.48 Published 1997 Journal Neurology Section Abstract Doc Link 9305323 Disease Relevance 1.12 Pain Relevance 0.14
In addition, the interaction between bupivacaine and rhEPO was investigated on human skeletal muscle myoblasts by fluorescence microscopy using mitotracker green and using the lipophilic cation JC-1.
rhEPO Binding (interaction) of in skeletal muscle myoblasts
5) Confidence 0.48 Published 2009 Journal Anesthesiology Section Body Doc Link 19212263 Disease Relevance 0 Pain Relevance 0
A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.
epoetin Binding (associated) of associated with anaemia and cancer
6) Confidence 0.37 Published 1998 Journal Drug Saf Section Title Doc Link 9804442 Disease Relevance 0.97 Pain Relevance 0
[Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
EPO Binding (combined) of associated with myelodysplastic syndromes and headache
7) Confidence 0.37 Published 2005 Journal Zhongguo Shi Yan Xue Ye Xue Za Zhi Section Title Doc Link 15972155 Disease Relevance 0.43 Pain Relevance 0.10
For example, the poorer outcomes observed in patients with breast or head and neck cancer have not been replicated in patients with small cell lung cancer.80,81 Whether this truly indicates a role for disease type in determining outcomes with ESA therapy remains to be seen.Is tumor EPO-R expression predictive of harm in patients receiving ESAs?
EPO Binding (remains) of in neck associated with lung cancer, cancer, disease and head & neck cancer
8) Confidence 0.37 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697520 Disease Relevance 0.86 Pain Relevance 0.09
In this context the therapeutic goal is to reduce the need for blood transfusion.Epoetin beta should not be used prophylactically to prevent anemia nor is epoetin beta approved for cancer-associated anemia in patients not receiving chemotherapy.Where chemotherapy is given with curative intent the risk:benefit ratio of epoetin therapy may be unfavorable and transfusion should be preferred.In all settings the risk:benefit ratio of transfusion versus epoetin therapy should be discussed with the patient.Patients should be iron replete and intravenous iron supplementation may be associated with enhanced response to ESA therapy.Epoetin beta dose should be titrated to the minimum which avoids need for transfusion as per the product label.Epoetin beta should be discontinued when Hb is >12 g/dL.Epoetin beta should be discontinued within 4 weeks of completing the course of chemotherapy.
Epoetin beta Binding (discontinued) of in blood associated with anaemia and cancer
9) Confidence 0.37 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697520 Disease Relevance 0.33 Pain Relevance 0.07
The role of EPO-R signaling in host cells is also of interest with compelling in vivo data supporting a role for EPO-R signaling in tumor neovascularization.71,72
EPO Binding (role) of associated with cancer
10) Confidence 0.37 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697520 Disease Relevance 0.53 Pain Relevance 0
The fact that recombinant Epo boosts maximal oxygen transport at sea level but not at high altitude implies the existence of an “altitude threshold” beyond which the ergogenic effect of rhEpo on V?
Epo Binding (recombinant) of
11) Confidence 0.37 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2500186 Disease Relevance 0.40 Pain Relevance 0
Treatment with Recombinant Human erythropoietin (rhEpo)
erythropoietin Binding (Treatment) of
12) Confidence 0.37 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2500186 Disease Relevance 0.18 Pain Relevance 0
O2max Depends on the Severity of Arterial Hypoxemia

Treatment with recombinant human erythropoietin (rhEpo) induces a rise in blood oxygen-carrying capacity (CaO2) that unequivocally enhances maximal oxygen uptake (V?

erythropoietin Binding (recombinant) of in blood
13) Confidence 0.37 Published 2008 Journal PLoS ONE Section Title Doc Link PMC2500186 Disease Relevance 0.46 Pain Relevance 0
Group A (17 patients) started with epoetin omega, and Group B (21 patients) started with epoetin alfa.
epoetin Binding (started) of
14) Confidence 0.36 Published 2002 Journal Artif Organs Section Abstract Doc Link 11879235 Disease Relevance 0.36 Pain Relevance 0
A patient who received epoetin (epo) or a transfusion was considered to have had a discussion of anemia.
epoetin Binding (received) of associated with anaemia
15) Confidence 0.36 Published 2007 Journal Current Oncology Section Body Doc Link PMC2133099 Disease Relevance 0.85 Pain Relevance 0
At the site of injection, only 1 patient described a mild pain when treated with epoetin omega and only 6 patients when treated with epoetin alfa.
epoetin Binding (treated) of associated with pain
16) Confidence 0.36 Published 2002 Journal Artif Organs Section Abstract Doc Link 11879235 Disease Relevance 0.64 Pain Relevance 0.10
We show that in response to axonal injury, periaxonal Schwann cells release erythropoietin (EPO), which via EPO receptor binding on neurons, prevents axonal degeneration.
EPO Binding (binding) of in neurons associated with injury
17) Confidence 0.36 Published 2004 Journal Ann. Neurol. Section Abstract Doc Link 15470751 Disease Relevance 0.61 Pain Relevance 0.06
We show that in response to axonal injury, periaxonal Schwann cells release erythropoietin (EPO), which via EPO receptor binding on neurons, prevents axonal degeneration.
erythropoietin Binding (binding) of in neurons associated with injury
18) Confidence 0.36 Published 2004 Journal Ann. Neurol. Section Abstract Doc Link 15470751 Disease Relevance 0.62 Pain Relevance 0.06
Additionally, EPO receptor-binding dependent biological effects attain their maximum several days after administration, when EPO serum levels have returned to baseline [14,34].
EPO Binding (binding) of
19) Confidence 0.36 Published 2005 Journal BMC Nephrol Section Body Doc Link PMC1164417 Disease Relevance 0 Pain Relevance 0
Epoetin therapy was associated with a significant reduction in blood transfusion from 27% of patients in the control arm to 14% in the epoetin arm (p < 0.001).
Epoetin Binding (associated) of in arm
20) Confidence 0.36 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697520 Disease Relevance 0.32 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox